Skip to main content

Advertisement

SpringerLink
Log in

Better outcomes for patients with gout

  • Commentary
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Gout is increasing in prevalence despite effective pharmacotherapies. Barriers to effective management are largely educational deficiencies. Sufferers, usually men, need to understand more about gout, especially that maintaining serum urate below 0.36 mmol/L will eliminate recurrent attacks. Also, of great importance is appreciating that sub-optimal adherence to urate-lowering therapy (ULT) will result in a return of attacks. Prescribers also need to understand that acute attacks are likely to occur in the first few months of urate-lowering therapy (ULT), but these can be mitigated by commencing with a dose of ULT reflective of renal function and escalating the dose slowly, every 2–5 weeks until target serum urate is achieved. Prophylaxis against acute attacks over the initial 6 months period of ULT can be enhanced further with concomitant colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs).

Gout is largely managed in primary care. Rates of adherence to ULT are 50% or less, worse than most other chronic illnesses. Efforts at educating primary care physicians to, firstly, manage gout effectively and, secondly, to educate their gout patients sufficiently have not been successful. Allied health practitioners, such as nurses, working with prescribers in primary care settings and given the mandate to educate and manage patients with gout, have been spectacularly effective. However, this approach is resource intensive. ‘Personalised’ eHealth interventions show promise as an alternative strategy, notably in improving adherence to ULT.

Numerous applications for smart phones (apps) are now available to assist people with chronic health conditions. Their design needs to accommodate the barriers and enablers perceived by patients to maintaining adherence to prescribed therapies. Personalised feedback of serum urate may represent an important enabler of adherence to ULT in the case of gout.

Harnessing mobile apps to support patients managing their chronic illnesses represents an important opportunity to enhance health outcomes. Rigorous, patient-centred and driven development is critical. These tools also require careful evaluation for effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Abhishek A, Doherty M (2018) Education and non-pharmacological approaches for gout. Rheumatol (Oxford) 57:i51–i58

    Google Scholar 

  • Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M (2017) Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care—5-year follow-up of a proof-of-concept study. Rheumatology 56:529–533

    PubMed  Google Scholar 

  • Bardin T, Richette P (2017) Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 15:123

    PubMed  PubMed Central  Google Scholar 

  • Batt C, Phipps-Green AJ, Black MA, Cadzow M, Merriman ME, Topless R, Gow P, Harrison A, Highton J, Jones P et al (2014) Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann Rheum Dis 73:2101–2106

    PubMed  Google Scholar 

  • Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31:2429–2432

    CAS  PubMed  Google Scholar 

  • Bowen-Davies Z, Muller S, Mallen CD, Hayward RA, Roddy E (2018) Gout severity, socioeconomic status, and work absence: a cross-sectional study in primary care. Arthritis Care and Research 70:1822–1828

    PubMed  Google Scholar 

  • Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437–443

    PubMed  PubMed Central  Google Scholar 

  • Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093–1103

    CAS  PubMed  Google Scholar 

  • Counsell AB, Nguyen AD, Baysari MT, Kannangara DRW, McLachlan AJ, Day RO (2018) Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Fam Pract 19:54

    PubMed  PubMed Central  Google Scholar 

  • Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392:1403–1412

    PubMed  PubMed Central  Google Scholar 

  • Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ, Jr Crowson CS, Matteson EL, Bongartz T (2017) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45(4):574–579

    PubMed  PubMed Central  Google Scholar 

  • Fernon A, Nguyen A, Baysari M, Day R (2016) A user-centred approach to designing an etool for gout management. Stud Health Technol Inform 227:28–33

    PubMed  Google Scholar 

  • Flynn TJ, Cadzow M, Dalbeth N, Jones PB, Stamp LK, Hindmarsh JH, Todd AS, Walker RJ, Topless R, Merriman TR (2015) Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. BMC Musculoskelet Disord 16:196

    PubMed  PubMed Central  Google Scholar 

  • Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO (2013) Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol 76:932–938

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56

    CAS  PubMed  Google Scholar 

  • Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM et al (2017) The British society for rheumatology guideline for the management of Gout. Rheumatol 56:e1–e20

    CAS  Google Scholar 

  • Jeyaruban A, Soden M, Larkins S (2016) General practitioners’ perspectives on the management of gout: a qualitative study. Postgrad Med J 92(1092):603–607

    PubMed  Google Scholar 

  • Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD (2017) Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol 83(9):2015–2026

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kot TV, Day RO, Brooks PM (1993) Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust 159:182–184

    CAS  PubMed  Google Scholar 

  • Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662

    PubMed  Google Scholar 

  • Lau AY, Piper K, Bokor D, Martin P, Lau VS, Coiera E (2017) Challenges during implementation of a patient-facing mobile app for surgical rehabilitation: feasibility study. JMIR Hum Factors 4:e31

    PubMed  PubMed Central  Google Scholar 

  • Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, Lee M, Perkovic V, de Zeeuw D, Mahaffey KW et al (2019) The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol 1:e220–e228

    Google Scholar 

  • Neogi T, Dalbeth N, Stamp L, Castelar G, Fitzgerald J, Gaffo A, Mikuls TR, Singh J, Vazquez-Mellado J, Edwards NL (2017) Renal dosing of allopurinol results in suboptimal gout care. Ann Rheum Dis 76:e1

    PubMed  Google Scholar 

  • Nguyen AD, Baysari MT, Kannangara DR, Tariq A, Lau AY, Westbrook JI, Day RO (2016) Mobile applications to enhance self-management of gout. Int J Med Inform 94:67–74

    PubMed  Google Scholar 

  • Nguyen AD, Frensham LJ, Wong MX, Meslin SM, Martin P, Lau AY, Baysari MT, Day RO (2018) mHealth app patient testing and review of educational materials designed for self-management of gout patients: descriptive qualitative studies. JMIR Mhealth Uhealth 6:e182

    PubMed  PubMed Central  Google Scholar 

  • Nuki G, Simkin PA (2006) A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 8:S1–S1

    PubMed  PubMed Central  Google Scholar 

  • Pérez-Ruiz F, So A, Kandaswamy P, Karra R, Kelton K, Perk S, Bardin T (2018) OP0162-HPR Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials. Ann Rheum Dis 77:132–132

    Google Scholar 

  • Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK (2017) The dietary approaches to stop hypertension (dash) diet, western diet, and risk of gout in men: prospective cohort study. BMJ 357:j1794

    PubMed  PubMed Central  Google Scholar 

  • Ramasamy SN, Korb-Wells CS, Kannangara DRW, Smith MWH, Wang N, Roberts DM, Graham GG, Williams KM, Day RO (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf 36:953–980

    CAS  PubMed  Google Scholar 

  • Ramsubeik K, Ramrattan LA, Kaeley GS, Singh JA (2018) Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 10:235–252

    PubMed  PubMed Central  Google Scholar 

  • Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen T, Janssens H et al (2020) 2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79:31–38

    PubMed  Google Scholar 

  • Rodriguez-Martin S, de Abajo FJ, Gil M, Gonzalez-Bermejo D, Rodriguez-Miguel A, Barreira-Hernandez D, Mazzucchelli R, Garcia-Lledo A, Garcia-Rodriguez LA (2019) Risk of acute myocardial infarction among new users of allopurinol according to serum urate level: a nested case-control study. J Clin Med 8(12):2150

    CAS  PubMed Central  Google Scholar 

  • Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A (2018) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 47:689–702

    PubMed  Google Scholar 

  • Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L (2014) The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73:1470–1476

    PubMed  Google Scholar 

  • Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N (2017) A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 76(9):1522–1528

    CAS  PubMed  Google Scholar 

  • Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N (2018) How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Res Ther 20:255

    CAS  PubMed  PubMed Central  Google Scholar 

  • Stamp LK, Wright DFB, Dalbeth N (2018b) Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate! Br J Clin Pharmacol 85.6(2019):1378–1379

    Google Scholar 

  • Tatlock S, Rudell K, Panter C, Arbuckle R, Harrold LR, Taylor WJ, Symonds T (2017) What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions. Patient 10:65–79

    PubMed  Google Scholar 

  • Vaccher S, Kannangara DRW, Baysari MT, Reath J, Zwar N, Williams KM, Day RO (2015) Barriers to care in gout: from prescriber to patient. J Rheum 43(1):144–149

    PubMed  Google Scholar 

  • Waldman B, Ansquer J-C, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD et al (2018) Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes and Endocrinol 6:310–318

    CAS  Google Scholar 

  • Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y (2019). Global, regional and national burden of gout, 1990–2017: a systematic analysis of the global burden of disease study. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez476

    Article  PubMed  Google Scholar 

  • Zgaga L, Theodoratou E, Kyle J, Farrington SM, Agakov F, Tenesa A, Walker M, McNeill G, Wright AF, Rudan I et al (2012) The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS ONE 7:e38123

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the National Health & Medical Research Foundation of Australia Partnership Grant # 1094708.

Author information

Authors and Affiliations

  1. St Vincent’s Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia

    Richard Day, Amy Nguyen, Eindra Aung, Mathew Coleshill & Sophie Stocker

  2. Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital, Sydney, Australia

    Richard Day, Garry Graham, Eindra Aung, Mathew Coleshill & Sophie Stocker

  3. Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia

    Amy Nguyen

  4. School of Medical Science, Department of Pharmacology, UNSW Medicine, Sydney, Australia

    Garry Graham

Authors
  1. Richard Day
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Garry Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eindra Aung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mathew Coleshill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sophie Stocker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Day.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Day, R., Nguyen, A., Graham, G. et al. Better outcomes for patients with gout. Inflammopharmacol 28, 1395–1400 (2020). https://doi.org/10.1007/s10787-020-00694-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-020-00694-7

Keywords

Search

Navigation